The present disclosure provides for methods of improving the efficacy of T cells. In an aspect, the disclosure further provides for methods of enhancing the persistence of T cells for adoptive cell transfer or therapy (ACT). Cytokine sensitivity assays (CSA) and associated methodology capable of predicting the persistence of adoptively infused T Cells are further provided for by way of the instant disclosure. The disclosure also provides for methods of treating cancer in a subject in need thereof as well as T cells populations produced by methods described herein.

The invention provides modified T-cell receptors referred to herein as dominant negative ligand-chimeric antigen receptors (DNL-CARS). The present invention also provides T-cells expressing DNL-CARs such T cells also referred to herein as DNL-CAR-expressing T cells or DNL-CAR T cells. Also provided are tagged-DNL/CAR-T systems that direct CAR-T cells to tumor cells previously complexed to the DNL-Tag fusion. Also provided are tagged-DNL-antigen fusion proteins wherein the antigen portion of the fusion proteins recruits the patient's own immune system to neutralize cells tagged with the tagged DNL portion of the fusion protein.

The present invention provides a chimeric antigen receptor, a NKG2D CAR-NK cell expressing the chimeric antigen receptor, and preparation and application thereof. The chimeric antigen receptor comprising an antigen binding domain, a transmembrane domain and a costimulatory signal transduction region, and the antigen binding domain can specifically bind to tumor specific antigen of NKG2D ligands and can activate NK cells through the transmembrane domain and the costimulatory signal transduction region. The NKG2D CAR-NK cell provided by the present invention use NKG2D ligands as target antigens, and can specifically kill tumor cells. It can be used as a therapeutic drug for tumor diseases, for the treatment of tumor with highly expressing of ligands of NKG2D molecule, thus providing new treatments for the tumors.

The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.

The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.

Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.

A method for preparing T cell populations for use in CAR T cell therapy and other immune cell therapies is described.

The present invention relates to methods for the specific separation of target cells from a biological sample, comprising specific binding of the target cells to phase-change hydrogel compositions and separation of respective cell-hydrogel complexes by counter-current centrifugation.

The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.